AL amyloidosis with renal involvement.
Primary (AL amyloidosis) is a systemic disease characterized by an amyloid deposition process in many organs, with unsatisfactory survival of patients. The monoclonal light chains form the fibrils that deposit and accumulate in tissues. Renal involvement is very frequent in AL amyloidosis and could lead to development of nephrotic syndrome followed by the renal failure in many cases. Classic therapeutic combination melphalan and prednisone has been supplemented with drugs with different mechanisms of action in this group of patients: high-dose dexamethasone, high-dose dexamethasone with melphalan, combination of vincristine, doxorubicin, and dexamethasone or newly high-dose melphalan supported by peripheral blood stem cell transplantation. This progressive therapy leads to the better survival and prognosis in the majority of patients. Alternative therapeutic approaches include thalidomide (alone or in combination with cyclophosphamide), lenalidomide, iododoxorubicin, etanercept and rituximab. The development of immunotherapy is expected in the near future.
Rysavá
Romana
R
Nephrology Clinic, 1st Faculty of Medicine, Charles University, Prague, Czech Republic. rysavar@vfn.cz
D000682:Amyloid / Q000378:metabolism; D000686:Amyloidosis / Q000150:complications* / Q000378:metabolism; D006801:Humans; D007167:Immunotherapy; D007668:Kidney / Q000378:metabolism; D009404:Nephrotic Syndrome / Q000209:etiology* / Q000378:metabolism / Q000628:therapy
D000682:Amyloid